Jump to: Page Content, Site Navigation, Site Search,
You are seeing this message because your web browser does not support basic web standards. Find out more about why this message is appearing and what you can do to make your experience on this site better.
BMJ 2006;332:1223-1224 (27 May), doi:10.1136/bmj.332.7552.1223
Let each patient choose among expectant, surgical, or medical management
| The first 150 words of the full text of this article appear below. |
Miscarriage in the first trimester affects about 15% of all pregnancies. It can be classified into early fetal loss (previously called missed abortion or blighted ovum) and retained products of conception (previously called incomplete abortion). Traditionally, both types of first trimester miscarriage are treated by surgical uterine evacuation. Increasingly, however, women are offered medical management (using misoprostol) or expectant management (avoiding treatment and letting the miscarriage take its natural course).
There have been numerous studies of miscarriage management, but they have generally been underpowered to assess anything other than the need for unplanned uterine curettage.12 The miscarriage treatment (MIST) study, a large, multicentre, randomised trial reported by Trinder and colleagues on p 1235, is therefore welcome.3
In the MIST study 1200 women with early fetal loss or retained products of conception were randomly allocated to receive expectant, surgical, or medical management. The primary outcome was infection, and there was
Andrew Weeks, senior lecturer in obstetrics
(aweeks@liv.ac.uk), School of Reproductive and Developmental Medicine, Liverpool Women's Hospital, Crown Street, Liverpool L8 7SS
Kristina Gemzell Danielsson, professor of obstetrics and gynaecology
Department of Woman and Child Health, Division for Obstetrics and Gynaecology, Karolinska Institutet, S-171 76 Stockholm, Sweden
Read all Rapid Responses